Vir Biotechnology
Vir Biotechnology
About

Vir is a science-driven company guided by medical need.

Vir integrates diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases. Vir is taking a multi-program, multi-platform approach to applying these breakthroughs, including the development of treatments that induce protective and therapeutic immune responses. Vir’s scale and scope, together with leading scientific and management expertise, allow it to perform significant internal R&D, in-license or acquire innovative technology platforms and assets, and fund targeted academic research.

Vir’s initial focus is in three areas of significant unmet need: chronic infectious diseases including hepatitis B, tuberculosis, and HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV); and health-care acquired infections.

The company was founded by Robert Nelsen and ARCH Venture Partners and seeded by ARCH, the Bill & Melinda Gates Foundation, Altitude Life Sciences, and Alta Partners. Additional investors include the SoftBank Vision Fund, Temasek, Baillie Gifford, the Alaska Permanent Fund, and select sovereign wealth funds, private individuals, family offices, and other institutional investors.

Vir is headquartered in San Francisco, California with operations in Portland, Oregon, Boston, Massachusetts, and Bellinzona, Switzerland

Read more

Type of organization

1 office
26-50
2016
Similar organizations
Swedfund International AB (Swedfund)
Swedfund International AB (Swedfund)
InstituteInvestment & FinanceService Providers
4 open positions
European Consumer Organisation (BEUC)
European Consumer Organisation (BEUC)
AssociationService Providers
1 open position
American Soybean Association
1 open position

Company Offices

  • United States (headquarters)
  • San Francisco
  • 499 Illinois Suite 500